| Bioactivity | Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis[1][2][3]. |
| Target | IL-23 |
| Invitro | Tildrakizumab 抑制表达人 IL-23Rα 和 IL-12Rβ1 受体的 HeLa 细胞中 IL-23 诱导的 STAT3 信号，IC50 为 23 pM[2]。Tildrakizumab 通过负变构调节降低 IL-23 对 IL-23Rα 的亲和力[2]。 |
| In Vivo | Tildrakizumab (100 mg/kg，皮下注射，每 2 周一次，最多 9 个月) 在食蟹猴中具有良好的耐受性 (毒性研究)[3]。 |
| Name | Tildrakizumab |
| CAS | 1326244-10-3 |
| Molar Mass | 144.4 (kDa) |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Papp K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9. [2]. Zhou L, et al. A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs. 2021 Jan-Dec;13(1):1964420. [3]. Santostefano M, et al. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates. Regul Toxicol Pharmacol. 2019 Nov;108:104476. |